The Thursday biotech signal
Capacity expands. Thursday hiring accelerates.
Lonza plans a commercial spray-drying facility in Bend with more than 80 initial jobs; 818 active biopharma opportunities added before cutoff are 42.3% above last Thursday.
JobReports original editorial image
818
Active biopharma jobs added
102
Biopharma employers
+42.3%
Versus last Thursday
163
Commercial & business roles
This dated issue is part of the public report archive. See the service update for account availability.
Commercial manufacturing / Bend
Lonza plans commercial spray-drying capacity with more than 80 initial jobs
Lonza plans to build a large-scale commercial PSD-4 spray-drying facility in Bend, Oregon. The company says the facility will contain two PSD-4 units, with room for future expansion, and is expected to be completed in 2029.
Lonza says the project will initially create more than 80 new jobs and extend its particle-engineering and bioavailability-enhancement work into a larger commercial-scale hub. The capital amount and hiring schedule were not disclosed.
Why it matters
A two-unit build-out points toward phased future work in process and facilities engineering, validation, quality, environmental controls, manufacturing operations, and particle science. The facility is planned, not yet operating.
Neuroimmunology / Priority Review
Roche's Enspryng application receives FDA Priority Review in MOGAD
The FDA granted Priority Review to Roche's supplemental application for Enspryng in myelin oligodendrocyte glycoprotein antibody-associated disease, with an action date of January 10, 2027. Roche says the Phase III METEOROID study showed a 68% relative reduction in adjudicated relapse risk versus placebo.
The result is company reported. Priority Review sets a shorter review goal; it is not approval and does not establish that commercial hiring will follow.
Hematology / Initial Phase 2 data
Disc reports early RESTORE-PV findings
Disc Medicine reported initial open-label Phase 2 results for bitopertin in polycythemia vera. Among 13 cohort A participants who completed 26 weeks, mean phlebotomies declined from 4.0 before treatment to 0.6 during treatment, and 61.5% were phlebotomy free.
The 13-person completed cohort sits within 40 participants enrolled overall. The data are preliminary, company reported, nonrandomized, and investigational.
Rare disease / Fast Track
Sobi's pacritinib receives Fast Track in VEXAS
The FDA granted Fast Track designation to Sobi's pacritinib for VEXAS syndrome. Sobi says the Phase II PAXIS study is ongoing.
Fast Track can support more frequent FDA interaction and potential review efficiencies. It is not approval and does not establish clinical benefit.
Respiratory medicine / Development financing
Ethris and the EIB sign €30 million in financing
Ethris and the European Investment Bank signed a €30 million financing agreement under HERA Invest. Ethris says the financing will support further clinical development of the nasal antiviral ETH47, including progress from Phase 2a toward Phase 2b studies in asthma and COPD, plus broader mRNA respiratory programs.
The financing provides capital for future execution; it does not represent completed clinical development, a guaranteed milestone, or a quantified hiring plan.
Thursday volume rises from last week
JobReports added 818 active biotechnology and pharmaceutical opportunities from 102 employers between midnight Eastern and today's cutoff. That is 42.3% above the 575 opportunities in the comparable Thursday window one week earlier. Commercial and business was the largest named role family, followed by clinical and medical work.
These are active opportunities first captured by JobReports before cutoff, not employer-supplied posting times. Role-family and location classifications are directional. The hiring sample is independent of today's news announcements and does not imply those companies created these jobs.
20
North Chicago roles
16
New York City roles
14
Rahway roles
13
Cambridge roles
Editor's shortlist
Five roles worth a closer look
Sr Automation Engineer
South San Francisco, California · On site
Senior Machine Learning Scientist I
Redwood City, California
Senior Associate Scientist, Scientific Writing
Columbus, Ohio
Aseptic Manufacturing Technician I — Day Shift A
Philadelphia, Pennsylvania · Contract to hire
Sr. Clinical Research Associate — Cardiac Catheter Products
United States · Remote
The takeaway
Planned capacity and advancing programs widen the execution map.
A commercial-scale facility carries a quantified future jobs signal. A Priority Review, early Phase 2 data, Fast Track status, and program financing each move different workstreams forward with clear evidence limits. Today's verified openings offer a separate route into automation, computational science, scientific writing, aseptic manufacturing, and clinical research.